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Hepatitis C virus (HCV) still represents amajor public health threat, with a dramatic burden fromboth epidemiological and clinical
points of view. New generation of direct-acting antiviral agents (DAAs) has been recently introduced in clinical practice promising
to cure HCV and to overcome the issues related to the interferon-based therapies. However, the emergence of drug resistance and
the suboptimal activity of DAAs therapies against diverse HCV genotypes have been observed, determining treatment failure and
hampering an effective control of HCV spread worldwide. Moreover, these treatments remain poorly accessible, particularly in
low-income countries. Finally, effective screening strategy is crucial to early identifying and treating all HCV chronically infected
patients. For all these reasons, even though new drugs may contribute to impacting HCV spread worldwide a preventive HCV
vaccine remains a cornerstone in the road to significantly reduce the HCV spread globally, with the ultimate goal of its eradication.
Advances in molecular vaccinology, together with a strong financial, political, and societal support, will enable reaching this
fundamental success in the coming years. In this comprehensive review, the state of the art about these major topics in the fight
against HCV and the future of research in these fields are discussed.
1. Introduction
Among infectious diseases, hepatitis C virus (HCV) still
represents a major public health threat, with a dramatic
burden fromboth epidemiological and clinical points of view.
Chronically infected individuals are estimated to reach 150–
170 million worldwide and estimates of incidence, performed
in the United States by the Center for disease control and pre-
vention (CDC), reported nearly 30,000 new HCV infections
in 2013 [1, 2].
Although HCV infection is characterized by a global dif-
fusion, its prevalence greatly differs according to geographic
area [3, 4]. Central Asia, Eastern Europe, the Midwest of
North Africa region, and Central and Western Sub-Saharan
Africa present high HCV prevalence rates, with figures
ranging between 3.1% and 5.4%; regions with intermediate
prevalence rates are Southern Sub-Saharan Africa, Central
Europe, Australia, and Latin America, with values between
1% and 1.4%; low prevalence is found in Oceania (0.1%),
Caribbean (0.8%), and Western Europe (0.9%) [3].
After acute infection, 75% of infected subjects become
chronically infected and approximately 20% of this popu-
lation develops liver cirrhosis during the two decades after
infection if left untreated [5, 6]. However, since in most cases
acute infection was asymptomatic, most HCV infections are
clinically silent until the disease reaches a late stage: HCV
was estimated to cause 25% of all cases of liver cirrhosis
and cancer worldwide and to account for more than 500,000
deaths per year [7].
In recent years, substantial advances have been made to
understand HCV biology and to develop a new generation
of effective direct-acting antiviral agents (DAAs) able to
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cure HCV. However, several challenges hamper an effective
control of HCV spread worldwide. In fact, the emergence of
drug resistance and the suboptimal activity of these therapies
against diverse HCV genotypes have been observed and have
been associated with treatment failure. Moreover, the high
costs of these drugs and the high prevalence of HCV-infected
individuals, especially in low-income countries, jeopardized
the affordability for the healthcare system to treat all infected
patients in developed countries and, even more, in develop-
ing countries [8, 9]. Finally, effective screening strategy is
required to early identify and treat all HCV chronically
infected patients thus limiting the infection transmission risk
as well as the progression to cirrhosis or hepatocellular carci-
noma and reducing the healthcare costs [10, 11]. For all these
reasons, a preventive HCV vaccine remains a cornerstone in
the road to significantly reduce the HCV spread globally.
This comprehensive review summarized the state of the
art about three major unresolved issues in the fight against
HCV: which are the perspectives for the universal screening
of HCV? Do we need DAAs resistance testing in the future?
How close is an effective preventive HCV vaccine?
2. Which Are the Perspectives for the
Universal Screening of HCV?
The rate of underdetection of HCV infection is still relevant
because of clinical, educational, technical, organizational, and
economic issues. In fact, recent estimates suggest that most
of people with HCV remain undiagnosed or unaware of their
HCV infection [12, 13].
Another criticism is represented by the difficulty in
early diagnosing HCV infection. Indeed, few people are
diagnosed during the acute phase because it is usually asymp-
tomatic [14]. Furthermore, the 55–85% of persons who do
not spontaneously clear the virus within 6 months develop
chronic infection and remain asymptomatic for decades after
infection, duringwhich infectionmay be transmitted to other
persons. Chronically infected patients usually become symp-
tomatic when the HCV-induced liver damage is advanced
and the therapy may be contraindicated [14]. The risk of late
diagnosis is associated also with the limited access to HCV
testing in many countries where HCV prevalence is high,
such as African and Central-East Asian countries [15].
Therefore, it is crucial to implement the most sensitive
and specific approaches to diagnose chronic HCV infection
before the development of liver damage and to assure the
linkage to care of infected patients [16].
2.1. Screening Tests for HCV Infection. A testing strategy for
HCV infections characterized by high sensitivity and speci-
ficity should be established.
The WHO recommends offering the HCV serology test
to individuals belonging to populationwith highHCVpreva-
lence or who have a history of HCV risk exposure/behavior
[14]. Given that HCV antibodies can be detected two months
following the infection and are also detectable in patients
who have cleared the virus, a positive result for antibodies
against viral proteins (anti-HCV) should be followed by a
nucleic acid testing using a reverse transcription polymerase
chain reaction (RT-PCR) for the detection of HCV RNA
and to confirm chronic HCV infection [14, 17]. Molecular
testing ismore technically demanding than the serology but it
guarantees positive results already after few weeks following
the exposure.
Among serologic screening test, the enzyme immunoas-
says (EIAs) are generally used [18]. EIAs are characterized
by high sensitivity and specificity, fast processing, high reli-
ability, relatively low costs, and the possibility of automation,
useful for large volume testing [19–21]. In particular, the third
generation test of EIAs is available [22] and has an estimated
sensitivity and specificity of 98.9% and 100%, respectively,
in patients with chronic liver disease [23]. However, the
serological windowperiod of this assay is generallymore than
40 days [24] and it should not be used in infants younger
than 18months because of the possible reactionwithmaternal
antibody [25].
Recently, the possibility of a single serologic assay for the
detection of HCV active infection has become available. This
test is based on the identification of the HCV core antigen
(HCVAg) that is detectable in acute infection almost at the
same time as HCVRNA [26] and persists during all phases of
infection [27], indicating its potential use as a less expensive
technique than molecular assays.
In consideration of improving the testing access, some
countries such as US [28] and France [29] validated the use
of Point of Care (POC) not only for HIV but also for HCV
infection screening. Although rapid tests have lower sensitiv-
ity than standard serological tests and require a specific orga-
nization to allow traceability of results, they are characterized
by relevant advantages such as the minimal equipment
required, the ease of obtaining the samples and of performing
the test, and the short time to obtain the results [30, 31].
However a recent meta-analysis that compared seven POC
demonstrated that OraQuick had the highest test sensitivity
and specificity and showed better performance than a third
generation enzyme immunoassay in seroconversion panels
[32]. The availability of POC rapid tests represents an oppor-
tunity to broaden the screening strategies to people outside
the healthcare structures [11], thus helping the achievement
of individuals at highest risk, such as people who inject drugs,
the homeless, and the incarcerated.
2.2. Identifying Patients with HCV. The variability of the
risk factors and history of behaviors linked to HCV infec-
tion, depending on the geographical setting and population
studied, make the identification of the target population for
screening policies challenging worldwide.
In many high-income countries HCV screening recom-
mendations are targeted to subjects with a history of HCV
risk exposure or behavior and certainmedical conditions and
who belong to a population of known high HCV prevalence
[33, 34]. In particular, at risk populations include those
who have received medical procedures such as hemodialysis
or dental interventions in healthcare facilities with inade-
quate infection control practices, persons who have received
blood transfusions, an organ transplant, or tissue graft
prior to the time when HCV serological testing of blood
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donors was introduced or in countries where it is not
routinely performed, subjects who inject drugs or who have
used intranasal drugs, persons who have received tattoos,
body piercing, or scarification procedures in settings where
infection control practices are substandard, children born to
mothers infected with HCV, healthcare workers who sus-
tained a needle stick or mucosal splash exposure from a
patient with HCV, and patients with HIV infection who have
unprotected sex with men, prisoners, and previously incar-
cerated persons (Class I, Level B recommendation) [10, 16,
35].
In 2012, the Center of Disease Control and Prevention
(CDC) and the US Preventive Services Task Force (USPSTF)
extended the HCV screening recommendation to all persons
born from 1945 through 1965, without prior ascertainment
of HCV risk factors (Class I, Level B recommendation) [35–
37]. The rationale of this recommendation is based on the
evidence that the risk-based strategy alone failed to identify
more than 50% of HCV infections because of healthcare
provider limitations in ascertaining risk factor information
[38, 39] and due to patients’ underreporting of their own
risk behaviors (e.g., injecting drug use) or exposure (e.g.,
iatrogenic infection). Furthermore, persons in the 1945 to
1965 birth cohort accounted for about 75% of all HCV infec-
tions, with a five times higher prevalence (3.25%) than other
persons [10, 37]. A recent retrospective review demonstrated
that 68% of persons with HCV infection would have been
screened through a birth cohort approach testing, while just
27% would have been identified with the risk-based strategy
[40]. The cost-effectiveness of one-time birth cohort test-
ing is comparable to that of current risk-based screening
strategies [36].Nevertheless, the implementation birth cohort
screening is challenging [10]. The inclusion of queries and
reminder flags among the electronic medical record (EMR)
could sensitize physicians [41]. However, various types of
EMR exist in USA and many reminders requiring time to
be addressed are triggered during each visit [10]. Further-
more, the identification of the best setting to implement the
screening of birth cohort represents a further issue. Available
evidences suggest that the hospital setting allows reaching
better results than the outpatients’ visits such as routine colon
cancer screening colonoscopy [42–45].
In Japan, where the overall prevalence ofHCV infection is
comparable with theUSA, but different transmission patterns
determined different age-specific prevalence, the national
screening for HCV in both the high-risk group and the
general population from ages 40 to 70 started at 2002 and has
demonstrated to be cost-effective in containing the epidemic
[46, 47].
In Europe, accurate estimates of HCV incidence and
prevalence are not available; however prevalence estimates
vary from 0.4% (Austria, Cyprus, Germany, Denmark,
France, and United Kingdom) to 1.5% (Israel and Italy)
in Western Europe and from 0.7% (Czech Republic) to
4.5% (Moldova) in Central and Eastern Europe [46]. HCV
screening programs are implemented for organ and blood
donors as well as for patients undergoing hemodialysis, but
not for risk groups such as injecting drug users, who currently
represent the leading cause of transmission across Europe
[48, 49]. Furthermore, the rising issue of fluid immigration
patterns from countries with high prevalence such as Egypt
has not been addressed yet [50].
Developing nations, where the population-based preva-
lence of anti-HCV may reach as high as 11% (Mongolia) to
15% (Egypt), are less likely to be able to afford screening [46].
Many of these countries are afflicted by political and social
unrest that may influence risk factors of HCV spread, such
as trauma, use of intravenous drugs, poor water and electric
supply, overcrowding, and lack of financial resources and
infrastructure [46].
Considering the existing barriers that limit the imple-
mentation of screening strategies such as low provider
knowledge about HCV and its related risk factors [13, 51–
54], the WHO Guidelines Development Group conducted a
systematic review to find the evidences about the most effec-
tive strategies to promote HCV testing [16]. Sensitizing the
practitioners about the importance of early HCV diagnosis
through in-service training sessions or mailed information,
provision of additional clinic staff, routine offer of testing to
all patients, or placing reminders in medical records resulted
more effectively in increasing uptake of testing, detecting
HCV antibody-positive cases, and the number of attendances
and referral to specialist care thanmedia-/information-based
targeted approaches (e.g., invitations to information sessions
for care providers, leaflets, and posters).
2.3. Recommendations for Frequency of HCV Screening Test-
ing. CDC and the US Preventive Services Task Force (USP-
STF) recommend a one-time HCV test in asymptomatic per-
sons belonging to the 1945 to 1965 birth cohort and subjects
with exposures, behaviors, and conditions that increase risk
for HCV infection.
As regards the correct periodicity of testing persons
at risk for ongoing exposure to HCV, evidence is lacking.
Thus, physicians should determine the frequency of testing
on the basis of the risk of reinfection. Owing to the high
incidence of HCV infection among HIV-infected men who
have unprotected sex with men and subjects who inject
drugs [55–60], the HCVGuidance by the Infectious Diseases
Society of America (IDSA) and the American Association
for the study of liver diseases (AASLD) recommended that
at least annual HCV testing is in these subgroups [35].
2.4. Linkage to Care. In order to enter the patients in the
cascade of care and thus provide them with the so-called
“continuum of care,” the detection of HCV-infected patients
should be followed by linkage to care via a physician referral
with expertise in evaluation and treatment HCV infection
[10, 61]. However, available evidences show that many gaps
between the HCV diagnosis and care cascade still exist [62,
63].
These gaps may be both patient- and practitioner-related.
The most common patient-related barriers to treatment
initiation include contraindications because of the presence
comorbidities, lack of acceptance, and access of treatment,
due to often asymptomatic course of the infection, long
treatment duration and possible adverse reactions of the
treatment, high cost, and distance to specialist [64–66]. In
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Table 1: Direct-acting antivirals (DDAs) approved for HCV treatment or investigated in clinical trials (updated in September 2016).
Class Generation Approved substances (developingcompany)
Substances currently tested in clinical trials












ABT-493 (AbbVie) [Phase 3]









Odalasvir (Janssen) [Phase 2]
Ravidasvir (Presidio) [Phase 2/3]
Second
generation
ABT-530 (AbbVie) [Phase 3]
MK-8408 (Merck) [Phase 2]




generation Sofosbuvir (Gilead Sciences)
MK-3682 (Merck) [Phase 2]






particular, the frequency and the severity of side effects
related to pegylated interferon and ribavirin (PEG-INF/RBV)
combination represent primary factors affecting both the
initiation of therapy and its continuation. The tolerability of
HCV therapy remained low also with the addition of first
generation DAAs (telaprevir and boceprevir) to the above-
mentioned therapeutic regimen [66]. The availability of new
generationDAAshas improved the tolerability of the antiviral
therapy [67].
Moreover, the linkage to care is critical among patients
coinfected with HIV [68, 69], those with underlying psychi-
atric and substance use disorders, and those with social insta-
bilities such as homelessness and incarceration [70].
General practitioner-related barriers include lack of
expertise in HCV treatment, lack of specialty referral resour-
ces, resistance to treating persons currently using illicit drugs
or alcohol, and concern about cost ofHCV treatment [71–73].
Evidence-based interventions to address linkage to care
have been summarized by Meyer JP and colleagues [61] and
by the HCV Guidance by the Infectious Diseases Society of
America (IDSA) and the American Association for the study
of liver diseases (AASLD) recommended that at least annual
HCV testing is in these subgroups [35].
These interventions include the integration of HCV
screening, evaluation, and treatment center with other med-
ical or social services, such as correctional facilities and pro-
grams providing needle exchange, substance abuse treatment,
and methadone maintenance [74–76]. Multidisciplinary case
management and social support have been demonstrated to
facilitate the efficacious treatment of HCV-infected patients
with psychiatric illness or substance use [77].
In order to address lack of access to specialists, models
involving close collaboration between primary care prac-
titioners and subspecialists also through telemedicine and
multidisciplinary networks of specialists have been imple-
mented [65, 78, 79]. Furthermore, the decreased duration and
better safety profile of current HCV therapy may increase the
number of mid-level practitioners and primary care physi-
cians able to appropriately manage and treat HCV infection
[35].
Additional strategies for improving linkage to and reten-
tion in care could be the use of patient navigators or care
coordinators [80, 81]; however, the efficacy and effectiveness
assessment of these interventions is still ongoing.
The extension of best and new strategies for linkage to
HCV care is essential to optimize the impact of HCV treat-
ment.
3. Do We Need DAAs Resistance Testing in the
Future?
Treatment of chronic hepatitis C has rapidly evolved from
PEG-INF/RBV to more potent highly effective DAAs com-
bination therapies. In particular, DAAs act on key stages of
the HCV lifecycle and are classified on the basis of their
molecular target and mechanism of action [82]. Four cat-
egories of DAAs are currently available: NS3/4A protease
inhibitors, NS5A inhibitors, nucleotide analogue inhibitors
of NS5B RNA-dependent RNA polymerase (RdRp), and
nonnucleoside inhibitors of RdRp. Table 1 summarizes DAAs
approved for HCV treatment. DAAs combination with other
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Table 2: Recommended regimen for the treatment of HCV with direct-acting antivirals-based combination therapies.








DCV + SOF (12 weeks)
LDV + SOF (12 weeks)a
SMV + SOF (12 weeks)c
OBV + PTV/r + DSV + R (12 weeks)
Strong Moderate
With cirrhosis
DCV + SOF (24 weeks)
DCV + SOF + R (12 weeks)
LDV + SOF (24 weeks)
LDV + SOF + R (12 weeks)b
SMV + SOF (24 weeks)c
SMV + SOF + R (12 weeks)c




DCV + SOF (12 weeks)
LDV + SOF (12 weeks)a
SMV + SOF (12 weeks)
OBV + PTV/r + DSV (12 weeks)
Strong Moderate
With cirrhosis DCV + SOF (12 weeks)LDV + SOF (12 weeks)
SMV + SOF (24 weeks)
SMV + SOF + R (12 weeks)
OBV + PTV/r + DSV + R (12 weeks)
2
Without
cirrhosis SOF + R (12 weeks) DCV + SOF (12 weeks)
Strong Low




DCV + SOF (12 weeks)
SOF + R (24 weeks)
Strong Low




DCV + SOF (12 weeks)
LDV + SOF (12 weeks)
SMV + SOF (12 weeks)
OBV + PTV/r + R (12 weeks)
Strong Moderate
With cirrhosis
DCV + SOF (24 weeks)
DCV + SOF + R (12 weeks)
LDV + SOF (24 weeks)
LDV + SOF + R (12 weeks)b
SMV + SOF (24 weeks)
SMV + SOF + R (12 weeks)c
OBV + PTV/r + R (24 weeks)
5
Without
cirrhosis LDV + SOF (12 weeks) SOF + PegIFN + R (12 weeks)
Conditional Very Low
With cirrhosis LDV + SOF (24 weeks)LDV + SOF + R (12 weeks)b SOF + PegIFN + R (12 weeks)
6
Without
cirrhosis LDV + SOF (12 weeks) SOF + PegIFN + R (12 weeks)
Conditional Very Low
With cirrhosis LDV + SOF (24 weeks)LDV + SOF + R (12 weeks)b SOF + PegIFN + R (12 weeks)
DCV: daclatasvir; LDV: ledipasvir; SMV: simeprevir; SOF: sofosbuvir; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; R: ribavirin; r: ritonavir; PegIFN:
pegylated interferon.
aTreatment may be shortened to 8 weeks in treatment-näıve persons without cirrhosis if their baseline HCV RNA level is below 6 million (6.8 log) IU/mL.The
duration of treatment should be shortened with caution.
bIf platelet count <75 × 103/𝜇L, then 24 weeks’ treatment with ribavirin should be given.
cIf positive for the Q80K variant, a simeprevir/sofosbuvir regimen should not be chosen.
DAAs and/or ribavirin has been widely investigated in clini-
cal trials and current recommendation by the World Health
Organization (WHO) for the treatment of HCV with DAAs-
based combination therapies is outlined in Table 2 [16]. Dur-
ing 2016, two novel DAAs combinations, grazoprevir/elbasvir
and sofosbuvir/velpatasvir, have been licensed in US and
Europe, and others are currently under evaluation in phases
II and III clinical trials and may be available in the coming
months [83].
The efficacy of treatment containing DAAs is very high
in terms of sustained virological response (SVR); nonetheless
10–15% of therapeutic failure is observed in clinical practice,
mainly associated with the selection of DAAs-resistant viral
variants, resulting from mutations produced by amino acid
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substitutions in the target virus protein that reduce viral sen-
sitivity to DAAs [84]. Resistance-associated variants (RAVs)
may be present, despite being usually at low levels even
before the beginning of DAAs treatment due to the great
genetic variability of HCV [84]. Moreover, genotype 3 virus
consistently demonstrates lower SVR rates to DAAs, despite
higher SVR rates in other forms of the virus [85].
Since DAAs are widely used for treatment of HCV, the
role of resistance-associated variants (RAVs) is becoming
clearer.
Natural polymorphisms, before treatment, associated
with resistance to NS3/4A, NS5A, and NS5B inhibitors have
a considerable prevalence in DAAs naı̈ve patients that is
variable and depends on HCV genotype and subtype [86].
These variants may be selected rapidly during treatment with
DAAswith the possible consequences of a viral breakthrough
and treatment failure [86–88]. For example, the preexist-
ing NS3/4A Q80K, mainly found in patients with HCV
genotype 1a (5%–48%), reduces SVR rates in genotype 1a
infected patients treated with the protease inhibitor simepre-
vir in combination with PEG-INF/RBV in comparison to
those without Q80K [89, 90]. In phase III clinical trials of
simeprevir and PEG-INF/RBV HCV genotype 1 and geno-
type 4 infected treatment-naı̈ve patients and prior relapsers
achieved SVR at week 12 rates of approximately 80% [91–
95]. Response rates to therapy were lower in HCV geno-
type 1 patients with Q80K compared with HCV genotype
1 patients without this polymorphism [7, 9, 11]. The Q80K
polymorphism is frequently observed in HCV genotype 1a
[96]; meanwhile the occurrence is close to zero in HCV
genotype 1b with the only exception of France where 11% of
genotype 1b has Q80K [97, 98]. On the basis of these data,
the European Medical Agency (EMA) and the Food and
Drug Administration (FDA) strongly recommend testing
for the presence of Q80K in HCV genotype 1a patients
who are candidates to therapy with simeprevir and PEG-
INF/RBV and discourage the use of this drug when Q80K is
detected.
In the IFN-free regimen the presence of Q80K was
associated with treatment failure only in a small sample
size of patients with genotype 1a and cirrhosis: a phase 3
study (OPTIMIST-2) evaluated the efficacy and safety of
12 weeks of simeprevir plus sofosbuvir in HCV genotype 1
infected treatment-näıve or treatment-experienced patients
with cirrhosis. Of the 72 patients with chronic HCV genotype
1a, SVR rate was lower for the 34 with Q80K at baseline
than for the 38 without Q80K (74% versus 92%) [99]. For
this reason, screening for the presence of the Q80K poly-
morphism should be considered before initiating simeprevir
in combination with sofosbuvir in cirrhotic patients infected
with HCV genotype 1a.
Reduced sensitivity to the first generation protease
inhibitors (PIs) (boceprevir and telaprevir) and to the more
recent PIs was associated with other NS3/4Amutations, such
as those involving the amino acid positions V36, T54, R155,
A156, and D168. The list of the major NS3/4A RAVs is
reported in Table 3.
The RAVs conferring resistance to NS5A inhibitors more
frequently occurred as natural variants in HCV G1 infected
patients näıve to DAAs [100] and seemed to be more prob-
lematic in the setting of retreatment. Y93H is the most
frequent baseline NS5A RAV in G1b, followed by L31M/V,
while NS5A RAVs are less frequent in G1a [86, 87, 101–
103]. L31M confers low-medium level resistance to daclatasvir
and ledipasvir, while Y93H/N confers medium-high level
resistance to all three approved NS5A inhibitors [100, 104] in
G1a but only for ledipasvir in G1b.
Recently, the FDA recommended testing for the presence
of virus with NS5A resistance-associated polymorphisms
(substitutions at amino acid positions 28, 30, 31, or 93)
in genotype 1a, regardless previous treatment history and
cirrhosis status, before the combination therapy with gra-
zoprevir and elbasvir to determine dosage regimen and
duration (for 12 or 16 weeks and if ribavirin should be added)
[101].
It is noteworthy that the persistence of NS5A RAVs
has been observed in about 85% of patients with treatment
failure over 1-2 years after the start of therapy [100, 105–
107]. Therefore, testing polymorphism could be useful prior
to retreatment decision because persistent NS5A RAVs could
impact the second line therapy success [90]. The list of the
major NS5A RAVs is reported in Table 4.
Regarding the NS5B RAVs, no cross resistance is ob-
served across currently approved nucleotide and nonnucleo-
side polymerase inhibitors. Nucleos(t)ide inhibitors demon-
strate activity against different HCV genotypes and have
a high resistance barrier [97]. The principal mutation that
confers decreased susceptibility to sofosbuvir is S282T and
more recently the variants L159F (with/without L320F and
C316N) and V321A were detected in patients with failed
treatment [108]. M414T and S556G variants were observed
in G1a and S556G in G1b patients who did not achieve an
SVR after a nonnucleoside analog inhibitor dasabuvir-based
regimen [104].Themost relevant NS5B RAVs are reported in
Table 5.
Resistance testing at baseline and following treatment
failure is not yet indicated, asmore data are needed to demon-
strate its role in clinical practice, but the unresolved issue is
if it may be useful to individualize the best treatment option
for each patient in the future. With the exception of Q80K
and NS5A RAVs detection in G1a patients before starting
simeprevir plus PEG-INF/RBV and grazoprevir plus elbasvir,
respectively, whether resistance mutation testing should be
done in treatment-näıve patients remains controversial.
Some authors highlight the importance of resistance
testing in patients who fail multiple DAAs for deciding
retreatment and selecting salvage therapy [90, 108, 109].
More recently, Sarrazin encourages also the baseline testing
in patients treated with a combination of a first generation
NS3/4A protease and NS5A inhibitor with a low barrier of
resistance. Instead, in case of treatment with high antiviral
activities and high genetic barrier to resistance, the evalu-
ation of additional predictors of response is to be assessed.
Moreover, baseline resistance testing may be used to choose
the best DAAs regimen in patients with shortened treatment
duration or with liver cirrhosis. Sarrazin sustained that in the
future it is to evaluate if baseline testing could be cost-effective
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10 Journal of Immunology Research
in order to prevent nonresponse to very expensive treatment,
particularly in regions with economical restriction [100].
4. How Close Is an Effective Preventive HCV
Vaccine?
Thedevelopment of an effective HCV vaccine is hampered by
several factors. First, HCV is characterized by an extraordi-
nary genetic variability resulting from the lack of proofread-
ing activity of the NS5B RNA-dependent polymerase [110].
This determines an impressive error rate per replication cycle
that, in combination with the short viral half-life and the
rapid turnover, leads to the generation of multiple distinct
but closely related HCV variants, known as “quasispecies,” in
one infected subject [111, 112].Mutated viruses have the ability
to persist in infected people by escaping immune control
of cytotoxic T lymphocytes (CTL) and antibodies against
different regions of the viral envelope [113, 114].
In addition to evading antibody and CTL recognition
by passively mutating its genome in response to immune
pressure, HCV exploits several further strategies to escape
adaptive immune response and achieve a high rate of chronic
infection. In fact, HCV, through a yet-unknown mechanism,
fails to properly initiate theCD4+Tcell response at the begin-
ning of infection and determines a rapid immune exhaustion
and depletion of CD8+ T cells [115–117]. Moreover, HCV
is able to hide from humoral immunity and pass from cell
to cell without being exposed to the circulating antibodies
by (i) binding low density lipoproteins, thus limiting the
production of neutralizing antibodies during acute infection,
(ii) decreasing viral immunogenicity through the presence of
three glycans at the CD81 binding site of E2 glycoprotein, (iii)
infecting surrounding cells through cell-to-cell contactmedi-
ated by CD81 and Claudin-1, and (iv) inducing interfering
antibodies by constant mutation [118].
The weaker and ineffective adaptive immune response to
HCV mainly contributes to the infection progressing into
a chronic state. On the other hand, these immune evasion
mechanisms have relevant implications in the development of
the HCV vaccine. In fact, an effective vaccine should be able
to induce strong neutralizing antibodies as well as powerful
cellular immune responses during the very first stages of the
HCV infection, before the virus has the chance to activate its
many immune escape mechanisms [119].
A further barrier that has challenged the research on
HCV vaccine is the lack of convenient experimental model
systems for the study of HCV pathogenesis and vaccine
design. To date, the only suitable infectious animal model
is the chimpanzee. However, some ethical issues, the high
cost of acquiring and maintaining the chimpanzees, and
their limited supply restricted the use of these animals
and the statistical power of studies [8, 120]. Furthermore,
immune response of chimpanzees to HCV greatly differs
from humans. Therefore, immunological results obtained
with this model should be prudently interpreted [121, 122].
Several strategies have been adopted to develop an
effective preventive HCV vaccine. They ranged from the
traditional strategy of producing recombinant envelope pro-
teins combining them with adjuvant substances to complex
manufacturing of viral vectors directing the expression of
multiple viral antigens. All strategies have been targeted to
enhance the T cell response and, in particular, to determine
a long-lasting cellular immune responses involving helper
CD4+ and CD8+ T cells rather than only improving humoral
responses.
Despite two decades of research efforts, few HCV candi-
date vaccines have reached the clinical trials phase and the
evidences on both the efficacy and safety of these vaccines in
humans remain limited (Table 6).
The first prophylactic HCV vaccine tested in human
beings was a C-terminally shortened recombinant E1 protein
adjuvantwith aluminumhydroxide, called T2S-918/InnoVac-
C, demonstrating good tolerability and good antibody
response against E1. Moreover, a robust specific cellular
immune response towards E1 was stimulated in all vaccinees
[123]. However, the studies on this candidate vaccine were
stopped in 2007.
Further HCV prophylactic vaccines based on recombi-
nant proteins combined with adjuvant substances have been
developed and evaluated in clinical trials.
A recombinant E1/E2 heterodimer vaccine (derived from
HCV 1a) adjuvant with MF59C was tested in phase I clinical
trial involving 60 healthy subjects. Vaccine demonstrated
inducing neutralizing antibodies and T cell responses to
E1/E2 in all subjects. Although the vaccine was safe and
well-tolerated, its usage was prevented by manufacturing
difficulties [124].
Another approach, based on recombinant protein, con-
sisted of combining recombinant HCV core protein with
an adjuvant substance, called ISCOMATRIX. In a phase
I clinical trial, conducted on 30 healthy volunteers, all
subjects except one demonstrated antibodies against HCV
core protein, without indication of a dose response. However,
T cell responses were detected in only two subjects who
received the highest dose of vaccine. The candidate vaccine
was generally well-tolerated [125].
Also the development strategies based on HCV peptides
vaccine that were able to induceHCV specific T cell responses
by presenting vaccine peptide to the T cell receptor via HLA
molecules have obtained some encouraging findings.
In particular, a peptide vaccine, known as IC41 and con-
sisting of five synthetic peptides derived from conserved
regions of core, NS3 and NS4 proteins of HCV genotypes 1
and 2 with a poly-L-arginine adjuvant, was evaluated in 128
healthy volunteers in a phase I clinical trial where it resulted
in being safe andwell-tolerated [126].On the other hand, IC41
elicited few interferon-producing cells and dose-dependent
T cell immune responses, even though a correlation between
higher responder rates with dose and number of vaccinations
was demonstrated [127]. In a successive randomized clinical
trial, 54 healthy subjects received either subcutaneous or
intradermal IC41 vaccine weekly (16 injections) or every
other week (8 injections). One group additionally received
imiquimod, an activator of the toll-like receptor (TLR) 7.
Results showed that IC41 induced significant immunolog-
ical responses in all groups with responder rates of up to
100%, even though imiquimod was not able to increase
immunogenicity but was associated with a lower immune
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response. Intradermal injections caused more pronounced
reactions, especially erythema and edema, but immunization
with IC41 resulted generally in being safe and well-tolerated
[127].
More innovative strategies to develop an effective HCV
preventive vaccine include the manufacturing of DNA vac-
cine and viral vectors expressing HCV genes. DNA vaccines
showed the capability of inducing cytotoxic lymphocyte
responses in animal models; however, the induced immunity
is often brief, weak, and unlikely to be effective in infection
prevention. Viral vectors able to express foreign antigens
represent an effective tool to induce a broader CD4+ and
CD8+ T cell responses, compared to peptide vaccines.
Two preventive vaccines based on human adenovirus
rare serotype 6 (HADV6) and chimpanzee Ad 3 (ChAd3)
expressing the HCV nonstructural proteins were tested in a
phase I clinical trial conducted on 36 healthy volunteers. The
study demonstrated that both vaccines induced by specific T
cell responses against multiple HCV proteins and T cell were
capable of recognizing heterologous HCV strains (genotypes
1a and 3a). These data suggested that an adenoviral vector
strategy may induce sustained T cell responses of a magni-
tude and quality associated with protective immunity, thus
encouraging studies of novel prophylactic vaccines for HCV
[128].
On the basis of some promising data obtained in phase
I clinical trials, different types of prophylactic HCV vaccine
are approaching phase II and phase III clinical trials [129].
In the next future, research efforts should be focused on
improving the selection of the viral component and the
proper administration regimens as well as on the safety and
the tolerability of candidate preventive HCV vaccines.
5. Further Therapeutic Options
Research efforts for the development of alternative therapeu-
tic options have been made contextually to the development
of DAAs and the research on preventive vaccines. To date,
several approaches have been adopted in the development
and production of HCV therapeutic vaccines including pep-
tide vaccines, recombinant protein vaccines, DNA vaccines
with different carriers, and virally vectored vaccines.
Some studies were conducted among chronic hepatitis
C patients, obtaining promising results in terms of T cell
proliferation and IFN-𝛾 responses and SVR rates within
patients treated with interferon [130, 131].
Clinical trials, conducted by administering candidate
HCV therapeutic vaccines in HCV chronic infected patients,
have demonstrated HCV specific immune responses and
transiently reduction of viral RNA, but the vaccines were not
able to completely clear HCV infection or consistently reduce
viral titers [130, 132, 133].
Some authors discussed the possibility to improve the effi-
cacy of these vaccines by prior treatment with DAAs to first
suppressHCVviremia [9], but the promising results obtained
with the new generation of DAAs and their combination in
curing HCV patients may overcome the use of therapeutic
vaccination as an effective strategy for HCV treatment.
A further therapeutic option to cure HCV is represented
by neutralizing monoclonal antibodies (mAbs) directed
against HCV envelope glycoproteins E1 and E2, which
are involved in the HCV entry into host cells or against
phospholipids expressed on infected host cells [134, 135].
With respect to mAbs directed against viral antigens, due
to the low immunogenicity of E1 glycoprotein, the research
mainly focused on mAbs targeted conserved regions of E2
glycoprotein. To date, two mAbs directed against this target
have been investigated in phase I and phase II clinical trials
in the prevention of HCV reinfection during and after liver
transplantation.
Two studies involved anti-HCV/2 human mAb HCV-
AB68 demonstrating only a modest and short-lasting reduc-
tion in viremia [136, 137]. More recently, MBL-HCV1 showed
good tolerability, reduced viral load, and delayedmedian time
to viral rebound compared to placebo treatment in a phase II
clinical trial involving 11 patients infectedwithHCVgenotype
1a [138].
As regardsmAbs against host receptors, a phase II unpub-
lished clinical trial involving bavituximab was conducted
to study the safety profile and early virological response in
HCV genotype 1 infected patients treated with this mAb
in combination with ribavirin in comparison with patients
treated with PEG-INF/RBV [135].
In recent years, novel mAbs with immunomodulatory
effects have been explored. Among these, mAbs that tar-
get programmed death 1 (PD-1), cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), and CD3 receptors were
studied in phase II clinical trials with encouraging results in
terms of safety, tolerability, and viral response [139–141].
The most likely future for clinical use of mAbs is rep-
resented by regimen for HCV treatment consisting of mAb
cocktails or combination of mAbs with other available drugs
with the main goal of avoiding viral escape and the develop-
ment of resistance.
6. Conclusions
Substantial advances have been made in HCV research and
treatment in recent years. Although highly effective anti-
HCVdrugs are now available, these treatments remain poorly
accessible because of their high costs; moreover, their efficacy
is challenged by the high frequency of resistance-associated
mutations. A further major obstacle for the control of the
disease is represented by the lack of availability of an effective
screening strategy to identify all people in need of treat-
ment. Therefore, even though new drugs may contribute to
impacting HCV spread worldwide, substantially modifying
the natural history of the disease, eradication will be reached
only through the development of an effective prophylactic
vaccine. Future research directions should bridge this gap and
progress in the comprehension of biological and immunolog-
ical mechanisms of the disease and advances in molecular
vaccinology, together with a strong financial, political, and
societal support, will enable reaching this fundamental suc-
cess in the coming years.
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